Literature DB >> 10910901

Highly efficient gene transfer in naive human T cells with a murine leukemia virus-based vector.

V Dardalhon1, S Jaleco, C Rebouissou, C Ferrand, N Skander, L Swainson, P Tiberghien, H Spits, N Noraz, N Taylor.   

Abstract

Retroviral vectors based on the Moloney murine leukemia virus (MuLV) have become the primary tool for gene delivery into hematopoietic cells, but clinical trials have been hampered by low transduction efficiencies. Recently, we and others have shown that gene transfer of MuLV-based vectors into T cells can be significantly augmented using a fibronectin-facilitated protocol. Nevertheless, the relative abilities of naive (CD45RA(+)) and memory (CD45RO(+)) lymphocyte subsets to be transduced has not been assessed. Although naive T cells demonstrate a restricted cytokine profile following antigen stimulation and a decreased susceptibility to infection with human immunodeficiency virus, it was not clear whether they could be efficiently infected with a MuLV vector. This study describes conditions that permitted gene transfer of an enhanced green fluorescent protein-expressing retroviral vector in more than 50% of naive umbilical cord (UC) blood and peripheral blood (PB) T cells following CD3/CD28 ligation. Moreover, treatment of naive T cells with interleukin-7 resulted in the maintenance of a CD45RA phenotype and gene transfer levels approached 20%. Finally, it was determined that parameters for optimal transduction of CD45RA(+) T cells isolated from PB and UC blood differed: transduction of the UC cells was significantly increased by the presence of autologous mononuclear cells (24.5% versus 56.5%). Because naive T cells harbor a receptor repertoire that allows them to respond to novel antigens, the development of protocols targeting their transduction is crucial for gene therapy applications. This approach will also allow the functions of exogenous genes to be evaluated in primary nontransformed naive T cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910901

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  IL-7 differentially regulates cell cycle progression and HIV-1-based vector infection in neonatal and adult CD4+ T cells.

Authors:  V Dardalhon; S Jaleco; S Kinet; B Herpers; M Steinberg; C Ferrand; D Froger; C Leveau; P Tiberghien; P Charneau; N Noraz; N Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

2.  Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation.

Authors:  Craig C Davis; Luciana C Marti; Gregory D Sempowski; Durairaj A Jeyaraj; Paul Szabolcs
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

3.  Changing viral tropism using immunoliposomes alters the stability of gene expression: implications for viral vector design.

Authors:  Peng H Tan; Shao-An Xue; Bin Wei; Angelika Holler; Ralf-Holger Voss; Andrew J T George
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

4.  Interleukin-7 signalling is sufficient to phenotypically and functionally prime human CD4 naive T cells.

Authors:  Elizabeth Z Managlia; Alan Landay; Lena Al-Harthi
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

Review 5.  Gene therapy in the treatment of intestinal inflammation.

Authors:  Catherine van Montfrans; Anje A te Velde; Sander J H van Deventer; Maria Sol Rodriguez Pena
Journal:  Int J Colorectal Dis       Date:  2003-06-25       Impact factor: 2.571

6.  Modalities of interleukin-7-induced human immunodeficiency virus permissiveness in quiescent T lymphocytes.

Authors:  Odile Ducrey-Rundquist; Mireille Guyader; Didier Trono
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation.

Authors:  Kazuko Shibuya; Jun Shirakawa; Tomie Kameyama; Shin-Ichiro Honda; Satoko Tahara-Hanaoka; Akitomo Miyamoto; Masafumi Onodera; Takayuki Sumida; Hiromitsu Nakauchi; Hiroyuki Miyoshi; Akira Shibuya
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.